

COVID-19: KEEPING UP WITH A MOVING TARGET MAY 13, 2020 UPDATE

Paul Auwaerter, MD, MBA, FIDSA

Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland






COVID-19 Keeping Up With A Moving Target

Now, Twice Every Week @ COVID19.DKBmed.com

Every Wednesday Evening

C**VID-19**
KEEPING UP WITH A MOVING TARGET

 **Dr. Paul Auwaerter**
Clinical Director
Division of Infectious Disease
Johns Hopkins University

Jointly provided by The Postgraduate Institute for Medicine and DKBmed, LLC.

Every Friday Morning

C**VID-19**
KEEPING UP WITH A MOVING TARGET

 **Sue Hansen, MSN, RN**
Trauma/Surgery Critical Care,
Clinical Nurse Specialist
UW Medicine at Harborview Medical Center

Jointly provided by The Postgraduate Institute for Medicine, DKBmed, LLC. and the Institute for Johns Hopkins Nursing



CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials. These include hydroxychloroquine/chloroquine, hydroxychloroquine/chloroquine in combination with azithromycin, lopinavir plus ritonavir, tocilizumab, corticosteroids, and COVID-19 convalescent plasma. All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.



CME Information

To attest for CME/CE credit, please visit

COVID19.DKBmed.com



Learning Objectives

- Discuss the effects of contact tracing.
- Describe testing modalities for COVID-19 illness.
- Review data from randomized controlled trials.



Paul Auwaerter, MD, MBA, FIDSA

Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland





Thank You

This program is brought to you through the generous support of DKBmed, Postgraduate Institute for Medicine, and the Institute for Johns Hopkins Nursing.

Please see **COVID19.DKBmed.com** for additional resources and educational activities



Communication Importance

PRovoke Covid-19 PR Industry Survey, second wave

From what you have seen, which government has impressed you MOST in terms of its Covid-19 communications?

Region



Not providing reliable information. Data given during the week contradicts the following. There is no trust from government sources..

Stickybeak Insight | Surveys





Testing and Contact Tracing

Coronavirus Disease 2019 (COVID-19)

CDC > Coronavirus Disease 2019 (COVID-19) > Health Departments > Support for Health Departments

[f](#) [t](#) [in](#) [✉](#) [🔔](#)

Coronavirus Disease 2019 (COVID-19)

Symptoms

Testing +

Prevent Getting Sick +

If You Are Sick +

Daily Life & Coping +

People Who Need Extra Precautions +

Pets & Other Animals +

Travel +

Frequently Asked Questions

Cases, Data, & Surveillance +

Communities, Schools & Workplaces +

Healthcare Professionals +

Contact Tracing

Get and Keep America Open: Supporting states, tribes, localities, and territories

[Print Page](#)

Summary of Recent Changes

Revisions were made on May 2, 2020, to reflect the following:

- A general re-organization of the page content

CDC guidance for COVID-19 may be adapted by state and local health departments to respond to rapidly changing local circumstances.

Key Concepts

- Trace and monitor contacts of infected people.** Notify them of their exposure.
- Support the quarantine of contacts.** Help ensure the safe, sustainable and effective quarantine of contacts to prevent additional transmission.
- Expand staffing resources.** Contact tracing in the US will require that states, tribes, localities and territorial establish large cadres of contact tracers.
- Use digital tools.** Adoption and evaluation of digital tools may expand reach and efficacy of contact tracers.

COVID-19
KEEPING UP WITH A MOVING TARGET

dkbmed



Testing



FDA Approves Oral (Saliva) Test




- Rutgers
 - Increasing production
- Others
 - Commercial
 - Gates Foundation
- Ease compared to NP-swab



Are Oral Samples Equivalent?

Detection of SARS-CoV-2 RNA in saliva vs. nasopharyngeal swabs



Wyllie A., et al. 2020




Treatment



Adaptive COVID-19 Treatment Trial (ACTT): Remdesivir

- Awaiting more analysis
- Trial is adapting—starting mid-May
 - RDV v. RDV plus baricitinib
 - JAK1/JAK2 subtype inhibitor, interferes w/ signal transduction STAT proteins, stopping gene expression in immunomodulatory cells





RDV Distribution Issues

The New York Times

The Coronavirus Outbreak >

LIVE

Latest Updates

Maps and Tracker

Lingering Symptoms

Life at Home

Newslett

Haphazard Rollout of Coronavirus Drug Frustrates Doctors

Remdesivir was shipped to small hospitals even as besieged medical centers were denied access.



Massachusetts General Hospital in Boston in March. Though other major hospitals did not receive supplies of remdesivir, Mass General did — without asking. “We have no idea how this landed with us,” said one doctor: Stan Grossfeld/The Boston Globe, via Getty Images



Triple Antiviral Combination Trial

THE LANCET

ARTICLES | [ONLINE FIRST](#)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

[Prof Ivan Fan-Ngai Hung, MD](#) • [Kwok-Cheung Lung, FRCP](#) • [Eugene Yuk-Keung Tso, FRCP](#) • [Raymond Liu, FRCP](#) • [Tom Wai-Hin Chung, MRCP](#) • [Man-Yee Chu, MRCP](#) • [et al.](#) [Show all authors](#)

Published: May 08, 2020 • DOI: [https://doi.org/10.1016/S0140-6736\(20\)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4) • [Check for updates](#)

- Open-label, randomized, phase 2 trial
- Hong Kong, (2:1) 14-day
 - Combination: lopinavir 400 mg/ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate day
 - Lopinavir 400 mg and ritonavir 100 mg every 12 h (control group)
 - Primary endpoint was the time to providing a nasopharyngeal swab negative



Triple Antiviral Combination Trial Findings

- 127 patients, 86 combination/41 control
- Median days symptom onset 5 days (IQR 3–7)
- Combination group
 - Reduced viral carriage x 5 days
 - Negative nasopharyngeal swab (7 days [IQR 5–11]) v. control group (12 days [8–15]; hazard ratio 4.37 [95% CI 1.86–10.24], $p=0.0010$)
 - Faster alleviation of symptoms x 4 days
 - NEWS2 of 0 (4 days [IQR 3–8] in the combination group vs 8 days [7–9] in the control group; HR 3.92 [95% CI 1.66–9.23], $p<0.0001$)
 - Adverse events included self-limited nausea and diarrhea with no difference between the two groups.
- Need for larger study, true placebo arm



HCQ + AZ Mortality

New Online Views 0 Citations 0 Altmetric 344 Comments

Download PDF

More ▾

Cite This

Permissions

Original Investigation

ONLINE FIRST FREE

May 11, 2020

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Eli S. Rosenberg, PhD¹; Elizabeth M. Dufort, MD²; Tomoko Udo, PhD¹; et al

» Author Affiliations | Article Information

JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630

25 hospitals, retrospective
N = 1438 patients


Adjusted HR in-hospital mortality

HCQ 1.08

Azithromycin 0.56

HCQ + AZ 1.35

None were statistically significant



No. at risk (in hospital)

	Admission	Day 7	Day 14	Day 21
Hydroxychloroquine + azithromycin	735	653 (384)	568 (106)	557 (47)
Hydroxychloroquine alone	271	245 (136)	226 (59)	220 (28)
Azithromycin alone	211	191 (33)	190 (4)	190 (2)
Neither drug	221	206 (63)	197 (19)	195 (13)



HCQ or CG Meta-Analysis

- 155 “studies” evaluated (preprint or published)
- No double blind, placebo-controlled RCT of high quality
- Data neither to endorse or to refute use of HCQ or CQ

this is review of 155 studies with 115 diff drugs
please check title

Fajgenbaum et al <https://www.medrxiv.org/content/10.1101/2020.05.07.20073981v1.full.pdf> (pre-print, release 5/11/20)



To submit your own question, please email
QA@dkbmed.com



Are recommendations changing surrounding precautions for pregnant women given the recent articles in *JAMA* and *The Lancet*, which showed increased risks of miscarriage, stillbirth, and preterm delivery in mothers who contracted COVID-19?



It has been discussed recently that there are potentially several different strains of this novel coronavirus. What are the latest research findings related to these different strains?



**What do we know about the inflammatory condition
being seen in children that has been associated with
COVID-19?**



Could you please comment on Sweden and New Zealand's disparate approaches to COVID-19?



To receive CME/CE credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question:

- Email QA@dkbmed.com